Core Viewpoint - OpenAI has confirmed its investment in brain-computer interface (BCI) startup Merge Labs, marking its entry into a cutting-edge technology sector with a significant seed funding of $252 million (approximately 1.76 billion RMB) [2][4]. Group 1: Investment Context - The investment was anticipated in mid-2025 and is notable for its size in the BCI field, indicating OpenAI's strategic interest in the evolution of human-AI interaction [2][4]. - OpenAI's involvement is seen as a long-term bet on the development of higher bandwidth human-AI interfaces, addressing the limitations of current interaction methods [5][14]. Group 2: Merge Labs' Approach - Merge Labs, co-founded by OpenAI's CEO Sam Altman and other tech entrepreneurs, is pursuing a distinct technological path in BCI development [6][9]. - The core direction of Merge Labs includes creating a BCI system that integrates biological, device, and AI attributes, aiming for a user-friendly technology that people are willing to adopt [9][10]. Group 3: Comparison with Neuralink - Merge Labs' philosophy contrasts with Neuralink, which focuses on invasive, high-density electrode systems for clinical applications [10][12]. - Merge Labs aims to explore non-invasive or low-invasiveness methods for long-term interfaces, potentially reducing tissue damage and enhancing user acceptance [13][14]. Group 4: Industry Implications - Merge Labs is currently positioned as a research lab rather than a product-focused medical device company, aligning with OpenAI's long-term vision [14]. - The investment signals a shift in how AI companies view the integration of human neural systems into their technological narratives, suggesting a broader exploration of human-AI connections [16]. Group 5: Market Potential - Analysts have estimated the potential market size for brain-computer interfaces to reach $400 billion, highlighting the significance of this technology in future human-AI interactions [15][16].

三诺生物（300298.SZ）1月6日在投资者互动平台表示，截至目前公司暂未开展人机接口领域相关业 务。公司相关信息请以公司官方渠道发布的信息为准。 每经AI快讯，有投资者在投资者互动平台提问：公司开展了相关人机接口分析服务吗？ （文章来源：每日经济新闻） ...

格隆汇1月6日丨三诺生物(300298.SZ)在投资者互动平台表示，截至目前公司暂未开展人机接口领域相 关业务。 ...

（文章来源：央视新闻） 据中国科学院深圳先进技术研究院消息，该研究院联合东华大学科研团队，历经5年多协同攻关，成功 研发出如头发丝般纤细、柔软可拉伸、可自由驱动的神经纤维电极"神经蠕虫"（NeuroWorm）。这项技 术标志着生物电子接口（脑机接口、人机接口）从静态走向动态、从被动记录走向主动智能探测的范式 转变。该研究成果北京时间9月17日在国际学术期刊《自然》发表。 ...